STOCKS TELEGRAPH

Tag: ZSAN

  • Zosano Pharma Corp. (ZSAN) stock Continues its Uptrend After Hours. Here’s why?

    On March 16, Zosano Pharma Corp. (ZSAN) rebounded during the regular session after a continuous downfall. The stock continued its uptrend in the after-hours as well. There is no official announcement or SEC filing from the company behind the stock’s comeback.

    During the regular session, the stock rallies by a huge 19.09% after fluctuating between $0.1551 and $0.1900. ZSAN closed the session at a price of $0.1840 per share while 15.48 million shares exchanged hands. The tock continued its uptrend into the following after-hours session to add a further 8.42%. Thus, ZSAN was trading at a value of $0.1995 per share at an after-hours volume of 1.64 million shares on Wednesday.

    The clinical-stage biopharmaceutical company, Zosano Pharma Corp. has a market capitalization of $26.49 million. Currently, the company has 171.46 million shares outstanding in the market.

    What is Happening with ZSAN?

    ZSAN stock had been in a downtrend for the past few days. After a persistent but mild downward spiral for a few days, the stock rebounded on Wednesday. Since there is no recent news or SEC filing, the stock seems to be moving due to external factors. It seems social media chatter, stock sentiment combined with the downtrend were the cause of the recovery. Investors seem to be buying the dip as it provided a good investment opportunity.

    ZSAN stock stands at a year-to-date loss of 60.85% while it lost 20.83% last month. Moreover, the stock subtracted a huge value of 87.48% in the past year.

    Upcoming Special Meeting

    Source: Corpbiz

    According to the SEC filing of February 25, the company will hold a special meeting of stockholders on April 8, 2022, at 8:30 am, ET. The purpose of the meeting is a Reverse Stock Split Proposal in the range of 1-for-5 to 1-for-50 for regaining compliance with Nasdaq’s minimum bid requirement.

    Furthermore, the meeting will take place virtually on the internet via a webcast.

    FDA’s Response Letter to ZSAN

    As per the company’s SEC filing of February 18, ZSAN received a response letter from FDA on February 17 regarding its NDA resubmission. The company had resubmitted its NDA for M207, zolmitriptan microneedle system on January 18. According to the letter, the resubmission failed to fulfill the previously identified deficiencies in the resubmission. Thus, FDA informed to not commence a substantive review of the application.

    Additionally, the company started to analyze and work over its best course of action regarding the NDA.

  • Zosano Pharma Corporation (ZSAN) stock plunged in the after-market. Here’s why

    Zosano Pharma Corporation (ZSAN) stock plunged in the after-market. Here’s why

    The stock of Zosano Pharma Corporation (ZSAN) ended the recent trading session at $0.16, gaining 31.62% from the previous session. During the last check, the stock of ZSAN lost 7.47% in the after-market, to $0.15. Recently, ZSAN’s petition for Zolmitriptan micro-needle was declined by the Food and Drug Administration. The company also filed the form DEF 14A with the SEC, on 25 February 2022.

    Zosano Pharma Corporation (ZSAN) is a clinical-stage pharmaceutical organization. ZSAN works around giving fundamental dispensing of medicine to patients utilizing its ransdermal micro-needle framework. Zosano accelerates drug integration into the blood circulatory system. The company has a market capitalization of $28.55 million, with 169.36 million of the pending shares. ZSAN has its base in Fremont, California, United States of America (USA).

    ZSAN’s News

    Recently, FDA declined the company’s petition for the Zolmitriptan microneedle system. A feedback report was disseminated to Zosano concerning the submission of 505(b)(2) medicine for M207. The reaction report expressed that the FDA didn’t ponder on the resubmitted application of M207. They will not start a meaningful audit of the application until they acquire a total reaction. Moreover, the company’s plan for laying out Zomig Nasal Spray 5 mg study was not satisfactory. ZSAN is assessing the subsequent stages. Notwithstanding, there can be no confirmations that the company will empower to keep chasing after FDA endorsement for M207.

    Moreover, on 8 February 2022, Zosano declared the pricing of its previous underwritten public offering. The offering included 51.2 million stocks, with one common share and one warrant, at a price of $0.30 for each stock. The warrants were exercisable immediately and had an expiry date of five years after the date of issue, with a price of $0.30 per stock. The aggregate profit for this offering was $15.4 million, prior to deducting guaranteeing limits and commissions.

    Further, the analysts at BTIG firm downgraded the stock rating of ZSAN from buy to neutral on 23 February 2022.

  • Zosano Pharma Corp. (ZSAN) stock Rolls Down After Hours on FDA Complete Response Letter

    On February 18, Zosano Pharma Corp. (ZSAN) filed a current report on Form 8-K with the SEC. According to the filing, the company has received a complete response letter regarding the recent resubmission of the New Drug Application for M207. Thus, the company’s resubmitted NDA was also deemed incomplete and unacceptable by the FDA. Consequently, the stock took a harsh hit in the after-hours on Friday.

    The stock was already trading in the red during the regular session at a volume of 9.24 million shares. ZSAN closed the session at $0.2159 with a loss of 3.49% after it reached a value of $0.2249. Following the SEC filing, the stock suffered a loss of 28.67% at 4.24 million shares. Hence, ZSAN stock was trading at a value of $0.1540 per share in the after-hours on Friday.

    The clinical-stage biopharmaceutical company, Zosano Pharma Corp. has a market capitalization of $37.02 million. Currently, the company has 171.46 million shares outstanding in the market.

    Recent Complete Response Letter

    Previously, the company had received a complete response letter from the FDA on October 19, 2020, regarding the NDA submission of M207. M207 is the companies investigational zolmitriptan transdermal microneedle system. The CRL highlighted the deficiencies in the NDA submission and suggested further studies and data provision. Therefore, the company conducted a Phase 1 PK study which was recently completed.

    On January 18, 2022, ZSAN resubmitted the 505(b)(2) New Drug Application for M207 with the FDA. As per February 18’s filing, the company received a response letter to the resubmission of February 17. According to the response letter, the company has failed to complete all the deficiencies highlighted in the previous CRL. So, the FDA will not be commencing a substantive review of the application unless a complete response is received.

    While the company is assessing its best course of action, there is no certainty as to whether it would be able to further pursue the NDA submission of M207. After the financial and strategic evaluation and planning, the company will decide upon a path.

    ZSAN’s Q3 Highlights

    In the third quarter of 2021, the company had a net loss of $8.7 million ($0.07/share), against $8.7 million ($0.11/share) in the year-ago quarter.

    ZSAN ended the quarter with cash and cash equivalents of $17.1 million on September 30, 2021. Comparatively, the company had $35.3 million on December 31, 2020.

  • Zosano Pharma Corp. (ZSAN) stock Nosedives After Hours on a Proposed Public Offering

    On February 08, Zosano Pharma Corp. (ZSAN) announced a proposed public offering of its common stock. As a result, the stock nosedived in the after-hours on Tuesday.

    The stock remained in the green during the regular trading session at a gain of 3.08%. ZSAN closed the session at $0.4726 with 3.5 million shares exchanging after reaching a high of $0.5025. Following the offering announcement, the stock took a hit to lose 36.10% at an after-hours volume of 2.8 million. Thus, ZSAN was trading at $0.3020, well below its 52-week low of $0.4100, in the after-hours on Tuesday.

    The clinical-stage biopharmaceutical company, Zosano Pharma Corp. is headquartered in Fremont, CA. Currently, its 118.35 million outstanding shares trade at a market capitalization of $54.26 million. ZSAN stock has added a mere 0.55% year to date while it suffered a huge blow of 76.25% last year.

    ZSAN: Proposed Public Offering

    On Tuesday, the company announced the initiation of an underwritten public offering. The offering will comprise of units having ZSAN’s common stock shares along with warrants to buy its common stock, sold by the company.

    Moreover, the sole book-running manager for the underwritten offering is Maxim Group LLC. Additionally, the actual size, terms, and completion of the offering were not disclosed in the press release. Hence, the company might be disclosing further details along with the pricing of the offering in a day or two.

    Publication of Clinical Data

    On January 05, the company announced the publication of its Phase 1 clinical trial data in the Journal of Vaccines and Immunology. The data was published in an article by the name “Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System”.

    According to the data, a low dose of a trivalent influenza vaccine through a transdermal microneedle system produced proper antibody levels. These antibody levels met the three mentioned efficacy guidelines of EMEA for influenza vaccine. Furthermore, the vaccine dose through the system was also well tolerated.

    ZSAN: Board Changes

    On December 13, ZSAN announced some changes to its Board of Directors. Firstly, Elaine M. Yang was appointed to Board. Ms. Yang currently serves as the Chief Revenue Officer at Lyra Health Inc. Before this, she has also served at executive positions with Facebook as well as Genetech.

    In addition, effective December 31, 2021, Kleanthis Xanthopoulos was announced to step down from the Board.

  • ZosanoPharma Corporation (ZSAN) stock plunged in the premarket trading here’s why

    ZosanoPharma Corporation (ZSAN) stock plunged in the premarket trading here’s why

    In the premarket trading session, ZosanoPharma Corporation (ZSAN) shares had plunged at last check by -3.27% to trade at the price of $0.977. ZSAN stock had previously closed the session on Tuesday while gaining 3.02% to close at $1.01. In the past 50 days, the ZSAN stock average volume of trading has been 2.44 million which is greater than today’s volume traded of 1.28 million shares. In the past year up to date has ZSAN shares rising by 24.23% and in the past week the shares have moved up by 9.30%. In the past three and six months, the stock has shed-12.17% and added 66.45%.

    What you need to know about ZosanoPharma Corporation

    ZosanoPharma Corporation is a biotechnology company that is specifically a clinical stage biopharma as well. ZSAN stock focuses on the production and provision of unique and novel treatments as well as therapeutics to meet the unmet needs of clients that are both health-workers and patients. The company has a platform where it develops therapeutics to reduce migraine for suffering patients along with other bioactive molecules which can work through using a transdermal microneedle system. The company’s lead investigative product candidate is used for the acute treatment of migraines. It is known as Qtrypta (M207) which is a proprietary formulation of zolmitriptan. The company was established in 2006 and is based in Fremont, California.

    ZosanoPharma Corporation is a leading biopharma that is specializing in the discovery and production of migraine treatments. Recent studies made by the ZosanoPharma have shown the effect of the Qtrypta on migraine suffering by reducing its frequency and pain. This holds a positive result for the potential of Qtrypta to be used as a long-term treatment solution for migraines.

    Zosano has made progress on its lead candidate Qtrypta’s long term study data

    The data obtained for this clinical trial was long-term data which is said to be published in the Journal of Headache and Pain. The safety and efficacy testing level of the trial suggested that it was tolerated consistently and showed no adverse effects while being tested in the Phase 2/3 ZOTRIP study.

    The long-term data of the study showcased that the pain frequency of the migraine had reduced for the patients observed in the study. The migraine attacks occurred on average 2 times per month for the selected patients and after taking Qtrypta dosage they obtaining relief while facing no serious side effects. The migraine attacks only lasted 2 hours after the Qtryota dose was administered, this result showed an efficacy of 81% in migraine attacks. Furthermore, the freedom of pain was for 44% of the attacks and had also reduced the worst and troubling symptoms of migraine attack by 62% of attacks.

    The administration of the dosage was majorly cutaneous application site where reactions were formed however these reactions were 95% mildly rated with 80% of the incidents of reaction resolved within 48 hours of application. This recent development has caused ZSAN stock shares to rise as it will with further milestones hopefully achieved in the future.

  • Zosano Pharma Corp. (ZSAN) Stock Trending Undergoes Minor Volatility Despite Promising Debt Management

    Zosano Pharma Corp. (ZSAN) Stock Trending Undergoes Minor Volatility Despite Promising Debt Management

    Zosano Pharma Corp. (ZSAN) stock prices were down by 3.77% as of the market closing on June 15th, 2021, bringing the price per share down to USD$1.02 at the end of the trading day. After-hours trading saw the stock fall by another 5.54%, bringing it down to USD$0.96.

    Importance of Debt

    Debt is bad for bad companies; but for good companies, debt is a tool that they can use to help them grow. The underlying assumption is the ability to pay off lenders, without the company carries immense inherent risk. Without a guarantee of the fulfillment of their legal obligations, shareholders could lose the entirety of their investments. Even it doesn’t come to the worst-case scenario, the shoring up of balance sheets could result in a dilution of company shares with the issuance of offerings to raise capital. Ideally, a company takes on dilution in the hopes of using that capital to reinvest and usher in growth that exceeds that dilution, otherwise taking on debt could be a cheaper option.

    Solid Liquidity Position

    As of March 2021, ZSAN reported USD$1.63 million in debt, as compared to not having any debt as of the March of the prior year. This debt is offset by a solid liquidity position of USD$26.9 million, resulting in net cash reserves of USD$25.3 million.

    Debt Safety

    ZSAN’s most recent balance sheets show liabilities in the amount of USD$14.4 being due over the course of the following 12 months, with liabilities of USD$8.15 million due beyond that. In conjunction with cash reserves of USD$26.9 million, the company reported USD$243,000 worth of receivables due over the year. Resultingly, ZSAN boasts liquid assets that amount to USD$4.57 more than total liabilities.

    Course of Action

    This comfortable ratio indicates a relatively conservative balance sheet, with the elimination of debt not seeming too difficult. With the safety of its debt assured, owing to the surplus of cash over debt, the company’s future earnings will dictate what course their balance sheet takes moving forward. In the absence of significant operating revenue, investors rely on the hope of hasty commercialization of ZSAN’s new medical technology.

    Future Outlook for ZSAN

    Armed with a solid liquidity position and very manageable debt, ZSAN is poised to continue its trajectory of success. The company is keen to usher in further growth with the effective allocation of capital and debt. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • The Zosano Pharma Corp. (NASDAQ: ZSAN) stock rises by 12.78% in afterhours. Here’s to know why:

    The Zosano Pharma Corp. (NASDAQ: ZSAN) stock rises by 12.78% in afterhours. Here’s to know why:

    Zosano Pharma Corp. (NASDAQ: ZSAN) stock showed a downswing by 5.00% in the last trading close whereas the stock rises in after-hours by 12.78%. There is no recent news or press release available, to be the exact reason behind this change in ZSAN stock price. On 11 March, ZSAN has announced its fourth quarter and fiscal year 2020 financial results which could might be the reason behind this up and down in Zosano Pharma stock price. Zosano Pharma Corp is a biopharmaceutical company that focuses on developing products with rapid administration of approved molecules and established safety and efficacy profiles to provide benefit to the patient whereas in the market people do not get the treatment that they need.

    Financial Results

    • ZSAN has reported a net loss of $8.1 million in the fourth quarter of 2020 as compared to $8.9 million in the fourth quarter of 2019. For full-year 2020, ZSAN stock has experienced a net loss of $33.4 million compared to $37.6 million for the full year 2019.
    • ZSAN has calculated its Research and Development expenses as $5.4 million in the fourth quarter of 2020 compared with $5.6 million for the same quarter of 2019. The decrease of $0.2 was mainly due to $0.4 million of lower employee and consulting expenses. For full-year 2020, the R&D expenses were $21.6 million compared with $25.4 million in full-year 2019.
    • General and administrative expense in the fourth quarter of ZSAN financial year was $2.6 million, while for the fourth quarter of 2019 it was $3.1million. For the full year 2020, the G&A expense was $11.2 million while it was $11.8 million for the full year 2019. The decrease of $0.5 million and $0.6 million is due to lower employee-related expenses.
    • Lastly, ZSAN recorded its cash and cash equivalents as $35.3 million which was previously calculated as $6.3 million as of December 31, 2019.

    Conclusion

    If we look closely at the financial results, ZSAN has made better progress as compared to the previous year despite the pandemic situation going on in the world. This could be a solid reason for investors to show their interest in ZSAN stock that has caused the rise in stock. Furthermore, ZSAN has signed few important agreements, one of which is with Mitsubishi Tanabe Pharma Corporation and partnerships with EVERSANA which is a promising sign for the future of Zosano Pharma Corp.

  • Early Morning Vibes: 4 Stocks We Like for Tuesday Trading

    Early Morning Vibes: 4 Stocks We Like for Tuesday Trading

    Major US stock indices fell 1.3-1.5% on the first day of trading in 2021.

    The broad market S&P 500 index fell 1.48% to 3700.65 points, the industrial Dow Jones Industrial Average fell 1.25% to 30223.89 points, and the technological NASDAQ dropped 1.47% 12698.45 points.
     

    Despite the general optimistic sentiment of investors regarding the recovery of the global economy after the coronavirus pandemic, the indices declined.

    At the start of the new year, investors focused on the same issue that has dominated the markets for much of 2020: the coronavirus pandemic. Many expect economic activity to accelerate later this year as communities are vaccinated, and organizations reopened. At the same time, there is an understanding that the path to economic recovery will be long and uneven.

    Recent news on the coronavirus situation paints a bleak picture. In the United States, the number of hospitalizations on Sunday reached a record high. In several countries in Europe, governments are extending quarantine restrictions designed to slow the spread of infection.

    The difficulty in dealing with the pandemic means that many companies will be vulnerable to financial risks in the short term.

    The experts noted growing nervousness over the results of the second round of elections to the U.S. Senate in Georgia. The outcome of the vote will determine whether the Republicans will retain control of the Senate. According to investors in prediction markets, the likelihood of a GOP victory has diminished in the past few days, potentially signaling a tense battle for Senate seats.

    Corporate Highlights

    Coca-Cola shares lost 3.8%. RBC Capital Markets has downgraded their rating from “above sector” to “par with the sector.” The bank’s analysts believe that the pandemic will continue to restrict public events and consumer access to restaurants, negatively affecting demand for Coca-Cola products.

    Airline stocks, which were also seriously affected by the coronavirus, also declined on Monday. In particular, American Airlines shares fell 4.1%, while Delta Air Lines shares fell 3.7%.

    Hotel chain shares were also down, with Hilton Worldwide Holdings down 3.4%, while Marriott International shed 5.4%.

    Tesla, meanwhile, gained 3.4%. The electric vehicle maker said it delivered a record 499,550 vehicles last year, just slightly below its target of 500,000.

    Amid a massive sell-off in shares, gold prices jumped 2.7% to $ 1,944.70 per troy ounce, the most significant percentage gain since April. Precious metal quotes usually receive support when market volatility increases.

    An additional source of joy in the market was the latest data on the manufacturing sector’s state. According to surveys of purchasing managers, factories in Asia and Europe increased their output at the end of the year. In December, there was a substantial rise in activity.

    Today Top Movers

    ‎Jaguar Health Inc (JAGX) share price ascended 30.90% to $2.33 during early morning ‎trading session on Tuesday.‎ ‎

    Zosano Pharma Corp (ZSAN), a Biotechnology company, increased about 78.60% ‎at ‎‎$1.04 in pre-market trading Tuesday after declaring that the company requested a Type A meeting with the U.S. Food and Drug Administration (FDA) to review resubmission plans for Qtrypta new drug application. ‎

    Naked Brand Group Ltd (NAKD) stock surged 14.83% at $0.25 in the pre-market trading today.

    Broadway Fin Cp (BYFC) jumped over 46.88% at $2.82 in pre-market ‎trading on Tuesday after the company and CFBanc Corporation revealed receipt of regulatory approvals for the merger.

    Top Upgrades & Downgrades


    Needham turned bullish on Merit Medical Systems Inc. (MMSI), upgrading the stock to “Buy” and assigning a $65.0 price target, representing potential upside of 18.69% from Monday’s close.
     

    DocuSign Inc. (DOCU) has won the favor of Piper Sandler’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $300.
     

    Cadence Design Systems Inc. (CDNS) received an upgrade from analysts at KeyBanc, who also set their one-year price target on the stock to $155.0. They changed their rating on CDNS to Overweight from Sector Weight in a recently issued research note.
     

    Earlier Sunday Piper Sandler reduced its rating on Fortinet Inc. (FTNT) stock to Neutral from Overweight.
     

    Piper Sandler analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Rapid7 Inc. (RPD) has been changed to Neutral from Overweight and the new price target is set at $95.
     

    Analysts at Piper Sandler downgraded Okta Inc. (OKTA)’s stock to Neutral from Overweight on Tuesday.

    Latest Insider Activity

    ReneSola Ltd (SOL) CFO SHAH CAPITAL MANAGEMENT announced the sale of shares taking place on Dec 31 at $11.90 for some 26,000 shares. The total came to more than $0.31 million.
     

    ACM Research Inc. (ACMR) Wang Jian sold on Dec 30 a total 84,386 shares at $78.00 on average. The insider’s sale generated proceeds of almost $2.53 million.
     

    Hall of Fame Resort & Entertainment Company (HOFV) Director Lichter Stuart declared the purchase of shares taking place on Dec 29 at $1.40 for some 10,813,774 shares. The transaction amount was around $15.14 million.
     

    Beyond Air Inc. (XAIR) CEO, Chairman Lisi Steven A. bought on Dec 31 a total 929 shares at $5.28 on average. The purchase cost the insider an estimated $203,280.

    Important Earnings

    Top US earnings releases scheduled for today include Cal-Maine Foods Inc. (NASDAQ:CALM). It will announce its Nov 2020 financial results. The company is expected to report earnings of -$0.08 per share from revenues of $333.49M in the three-month period.

  • 20 Trending Stocks In Biotechnology Industry That Need Your Attention

    20 Trending Stocks In Biotechnology Industry That Need Your Attention

    Biotechnology is considered to be the backbone of many industrial sectors and it makes a significant contribution to the well being of society. Every single day we saw changes in every sector as we experience advancements of knowledge and the new technological breakthroughs.  One of the industries that constantly change is the biotechnology industry.

    2020 is the year of continuous development and improvement in drug research. This industry is the leading rapidly growing sector of the economy. There are various trends in the biotechnology industry that the world should expect in the coming years such as the production of personalized medicines thanks to the advancement in genetics and continuous development and improvement in drug research.

    Let’s take a quick look at the 20 leading companies which are following new trends in the biotechnology sector:

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) shares were trading up 46.79% at $7.78 at the time of writing on Monday. Vaxart Inc. (NASDAQ: VXRT) share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.78. VXRT market cap has remained high, hitting $766.25M at the time of writing, giving it a price-to-sales ratio of more than 90.

    Vaxart Inc. has revealed that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. Vaxart Inc. also gave an update on its COVID-19 program.

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $7.75, in a 52-week range of $1.05 to $10.95. Cassava Sciences has announced the final results of a Phase 2bclinical study of Sumifilam in patients with Alzheimer’s Disease. Sumifilam is the first of a new class of drug compounds that bind to a protein called Filamin A. Cassava Sciences Inc. (SAVA) has earlier held a conference call on September 14.  Cassava Sciences Inc.’s market cap has remained high, hitting $182.51 million at the time of writing.

    Immunomedics Inc. (IMMU)

    Immunomedics Inc. (IMMU) stock soar by 97.99% to $83.65. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Gilead Sciences Inc. (NASDAQ: GILD) has earlier announced that it has decided to buy biotech company Immunomedics Inc for $21 billion. This decision will strengthen its cancer portfolio by gaining access to a promising drug.  Immunomedics Inc. (IMMU) has a total market capitalization of $19.19 billion.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares headed rising, higher as much as 17.88%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (NASDAQ: SRNE) has earlier disclosed that it has signed an exclusive license agreement with Mayo Clinic for an antibody-drug-nanoparticle albumin-bound (nab) immune complexes (ADNICs) platform targeting many types of human diseases including various solid and liquid tumors. Sorrento Therapeutics Inc. has a market cap of $1.86 billion.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) rose 13.00% after gaining more than $0.06 on Monday. Novan Provides Pipeline and Priority Development Programs Update. Novan Inc. (NOVN) gave a pipeline and priority development programs update. Novan Inc.’s share price went from a low point around $0.22 to briefly over $3.72 in the past 52 weeks, though shares have since pulled back to $0.53. Novan Inc.’s market cap has remained high, hitting $82.02 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 12.30% to $11.32. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has earlier signed a manufacturing agreement with Thermo Fisher Scientific. Thermo Fisher Scientific has signed a letter of intent to manufacture INOVIO’s DNA COVID-19 vaccine candidate INO-4800.

    Evofem Biosciences Inc. (NASDAQ: EVFM)

    Evofem Biosciences Inc. (NASDAQ: EVFM) Shares headed rising, higher as much as 11.90% after Evofem Biosciences to present data at the 2020 STD prevention Virtual Conference from Phase 2b Trial of EVO100 for prevention of Chlamydia and Gonorrhea in Women. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 9.28% after gaining more than $0.18 on Monday. iBio Inc. (AMEX: IBIO) has earlier disclosed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection. iBio revealed earlier the preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute, induced anti-SARS-CoV-2 antibodies.  iBio Inc has a market capitalization of $379.31 million.

    Clovis Oncology Inc. (CLVS)

    Clovis Oncology Inc. (CLVS) last closed at $7.00, in a 52-week range of $2.93 to $17.37. CLVS has traded up 138.91% from its 52-weeks low and traded down -59.70% from its 52-weeks high. Analysts have a consensus price target of $9.00. Clovis Oncology Inc. (CLVS) has earlier announced Oral Plenary Session Presentation at the International Gynecologic Cancer Society (IGCS)digital annual global meeting.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 1.82% to $1.12. The most recent rating by ROTH Capital, on June 20, 2016, is at a Buy. Heat Biologics Inc. (HTBX) has earlier participated in a virtual panel, entitled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10. Heat Biologics has also issued a key patent on combination platform therapy. Heat Biologics Inc. has a total market capitalization of $170.96 million.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) shares headed rising, higher as much as 12.82% after VBI Vaccines to present additional biomarker data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy. Its market capitalization has remained high, hitting $813.82 million.

    Dynavax Technologies Corporation (NASDAQ: DVAX)

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 13.37% after gaining more than $0.67 on Monday. Valneva and Dynavax have announced a Commercial supply agreement for Inactivated, adjuvanted COVID-19 vaccine. This is a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant for use in Valneva’s SARS-CoV-2 vaccine candidate, VLA2001. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the opportunity to purchase up to an additional 90 million doses through 2025.

    Zosano Pharma Corporation (NASDAQ: ZSAN)

    Zosano Pharma Corporation (NASDAQ: ZSAN) last closed at $1.72, in a 52-week range of $0.41 to $2.45. Zosano Pharma Corporation (ZSAN) is scheduled to participate in a Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020. At the conference, Zosano Pharma Corporation will present the company overview. Zosano Pharma Corporation has a total market capitalization of $138.86 million at the time of writing.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) stock soar by 7.30% to $63.67. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier named Michael Millette as Managing Director, Canada effective immediately. Michael Millette has joined Moderna Inc in August 2020 as Vice President. Moderna Inc has a total market cap of $24.37 billion at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NASDAQ: NMTR) Shares headed rising, higher as much as 12.61%. 9 Meters Biopharma Inc. (NASDAQ: NMTR) is scheduled to participate in the upcoming two conferences in September including H.C. Wainwright: 22nd Annual Global Investment Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. These two conferences are scheduled to take place on September 15 and September 23, respectively.

    Ampio Pharmaceuticals Inc. (AMEX: AMPE)

    Ampio Pharmaceuticals Inc. (AMEX: AMPE) rose 10.80% after gaining more than $0.08 on Monday. Ampio Pharmaceuticals Inc. (AMPE) has revealed positive results in the early trial for intravenous Ampion treatment for COVID-19 patients on September 9, 2020. The Phase I trial was continued in the supervision of Michael Roshon, MD, Ph.D., Chief of Staff at Penrose-St. Francis Hospital in Colorado Springs, Colorado.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) last closed at $105.80, in a 52-week range of $3.54 to $189.40. Novavax Inc. (NVAX) is scheduled to participate in the upcoming three conferences including Cantor Virtual Global Healthcare Conference, Morgan Stanley Virtual 18th Annual Global Healthcare Conference, and Leerink CyberRx Series: Vaccine Forum on September 15, 16, and 23, respectively. It has earlier participated in Citi 15th Annual BioPharma Virtual Conference, and H.C. Wainwright 22nd Annual Global Investment Conference on September 10, and 14, 2020, respectively.

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS)

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) stock soar by 5.50% to $2.11. The most recent rating by H.C. Wainwright, on July 01, 2020, is at a Buy. Marinus Pharmaceuticals Inc. (MRNS)has disclosed that it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE).

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.28%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (NASDAQ: ONTX) has earlier participated in two virtual events including Marcus Evans Healthcare Investment Webinar on September 10 and H.C. Wainwright 22nd Annual Global Investment Conference onSeptmerb 14. It is scheduled to participate in the 2nd Annual RAS-Targeted Drug Development Conference on September 16, 2020.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) last closed at $2.08, in a 52-week range of $0.46 to $3.68. In the past 52-weeks of trading, Trevena Inc. (TRVN) stock fluctuated between the low of $0.46 and a high of $3.68. It has moved up $352.17% from its 52-weeks low and moved down -43.48% from its 52-weeks high. Its market capitalization is $306.38 million at the time of writing.